MET and non-small cell lung carcinoma: A phase II study investigated the therapeutic efficacy of a cMET inhibitor, INC280 or Capmatinib in combination with gefitinib for NSCLC patients with EGFR-TKI resistance and cMET positive, which demonstrated ORR of 18% (12/65) and DR of 62% (40/65) [108].